Last reviewed · How we verify
Different HAART regimens
Different HAART regimens is a Antiretroviral combination therapy Small molecule drug developed by Danish HIV Research Group. It is currently FDA-approved for HIV-1 infection (treatment and viral suppression), AIDS prevention and management.
HAART regimens suppress HIV replication by combining multiple antiretroviral drugs that target different stages of the viral life cycle.
HAART regimens suppress HIV replication by combining multiple antiretroviral drugs that target different stages of the viral life cycle. Used for HIV-1 infection (treatment and viral suppression), AIDS prevention and management.
At a glance
| Generic name | Different HAART regimens |
|---|---|
| Sponsor | Danish HIV Research Group |
| Drug class | Antiretroviral combination therapy |
| Target | HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Highly Active Antiretroviral Therapy (HAART) typically combines nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs) to simultaneously block reverse transcription and protease-mediated viral maturation. This multi-drug approach prevents the emergence of drug-resistant viral strains and achieves sustained viral suppression, allowing immune reconstitution in HIV-infected patients.
Approved indications
- HIV-1 infection (treatment and viral suppression)
- AIDS prevention and management
Common side effects
- Nausea and gastrointestinal disturbance
- Lipodystrophy (fat redistribution)
- Peripheral neuropathy
- Hepatotoxicity
- Hyperlipidemia
- Lactic acidosis (rare)
- Immune reconstitution inflammatory syndrome (IRIS)
Key clinical trials
- Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
- Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients (PHASE4)
- Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Different HAART regimens CI brief — competitive landscape report
- Different HAART regimens updates RSS · CI watch RSS
- Danish HIV Research Group portfolio CI
Frequently asked questions about Different HAART regimens
What is Different HAART regimens?
How does Different HAART regimens work?
What is Different HAART regimens used for?
Who makes Different HAART regimens?
What drug class is Different HAART regimens in?
What development phase is Different HAART regimens in?
What are the side effects of Different HAART regimens?
What does Different HAART regimens target?
Related
- Drug class: All Antiretroviral combination therapy drugs
- Target: All drugs targeting HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)
- Manufacturer: Danish HIV Research Group — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection (treatment and viral suppression)
- Indication: Drugs for AIDS prevention and management
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing